Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced a partnership with Emiliem, Inc. to screen the company's multi-kinase inhibitors using Invitrogen's SelectScreen(TM) platform. Invitrogen will perform biochemical kinase screening, cellular pathway profiling and P450 screening of Emiliem's compounds targeting cancer. Financial details of the multi-year agreement were not disclosed."We are fortunate to have a partner with the highest technical and scientific standards in the industry and unmatched cellular screening assays," said Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem. "We view Invitrogen as a key component of our research arm in our quest to bring innovative therapeutics to cancer patients."
Invitrogen's SelectScreen(TM) profiling and screening service integrates industry-leading enzyme collections and cell-lines with state-of-the-art bioassay technologies to accelerate drug discovery programs. The first phase of the agreement will use the SelectScreen(TM) kinase profiling system to confirm specificity and potency of compounds in the Emiliem pipeline created through its K-STAR technology - a proprietary drug design platform for creating compounds that inhibit multiple kinases and other cellular targets known to be important in cancer progression. The second phase will use Invitrogen's SelectScreen(TM) cell-based pathway profiling service to interrogate the effects of Emiliem's compounds on biological pathways and the company's cytochrome P450 profiling service to determine the inhibitory profiles of lead molecules against drug metabolizing liver enzymes.
"Our services will provide critical information to Emiliem, including confirmation that Emiliem's compounds act on the kinases they are targeted to, determination of the compounds' effects on specific biological pathways and prediction of potential toxicity," noted Nick Ecos, Vice President and General Manager of Invitrogen's Discovery Sciences business. "Our selection for this research partnership demonstrates our strong credentials in kinase biology and small molecule screening."
About Emiliem
Emiliem, Inc. is a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs. The company has developed proprietary drug design technologies that facilitate the inclusion of multiple kinase inhibitor profiles into single compounds. Emiliem's approach to developing targeted drugs includes the ability to identify proprietary biomarkers. Coupling drug discovery with biomarker identification and implementation increases the likelihood of achieving clinical trial endpoints and receiving approval to market these innovative drug candidates. The company is headquartered in Emeryville, California. For more information, visit www.emiliem.com
About Invitrogen
Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company is celebrating 20 years of accelerating scientific discovery. Invitrogen globally employs approximately 5,000 scientists and other professionals and had revenues of more than $1.26 billion in 2006. For more information, visit www.invitrogen.com
No comments:
Post a Comment